BEBT-109, a pan-mutant-selective EGFR inhibitor with potent antitumor activity in EGFR-mutant non-small cell lung cancer

EGFR mutation-positive NSCLC tumors are highly heterogeneous, therefore, exploring an agent simultaneously targeting multiple EGFR mutations may be valuable for clinical practice. Compared with osimertinib, BEBT-109 shows more sensitive and extensive antitumor activity in EGFR mutant NSCLC, while sp...

Descripción completa

Detalles Bibliográficos
Autores principales: Fan, Fushun, Zhou, Minhua, Ye, Xiaolan, Mo, Zhenxian, Ma, Yaru, Luo, Liying, Liang, Xiaotong, Liu, Haiqi, Weng, Yunwo, Lin, Mingsheng, Liu, Xinjian, Cai, Xiong, Qian, Changgeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2020
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745057/
https://www.ncbi.nlm.nih.gov/pubmed/33321427
http://dx.doi.org/10.1016/j.tranon.2020.100961

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7745057/
https://www.ncbi.nlm.nih.gov/pubmed/33321427
http://dx.doi.org/10.1016/j.tranon.2020.100961

Ejemplares similares